Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose onalespib when given together with
paclitaxel in treating patients with triple negative breast cancer that has spread to other
places in the body and usually cannot be cured or controlled with treatment (advanced).
Onalespib works by blocking proper processing of proteins that are important for cancer
growth. This results in inability of these proteins to work properly. Paclitaxel kills breast
cancer cells by interfering with their ability to divide. Giving onalespib together with
paclitaxel may be better than giving either one alone in treating patients with breast
cancer.